PROCEPT BioRobotics Corp
PROCEPT BioRobotics Corp develops and commercializes robotic systems for urology procedures, centered on Aquablation therapy for benign prostatic hyperplasia (BPH). The company sells its systems, single-use handpieces, accessories, and related service offerings primarily in the United States, with additional commercial activity in international markets through direct sales and distributors.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCapital equipment used to deliver Aquablation therapy in urology procedures.
Disposable handpieces used during each Aquablation procedure.
Ancillary components shipped with or used alongside the robotic systems.
Maintenance, repair, and support services for installed systems.
Sales-type leasing arrangements and other related commercial revenue.
Customers
The company sells primarily to hospitals in the United States, where the end users are urologists and surgical teams performing BPH procedures. Outside the U.S., it works through direct sales teams and distribution partners, with market access shaped by reimbursement, surgeon training, and regulatory approval pathways.
Primary buyers of robotic systems and disposables for hospital-based BPH procedures.
Clinical decision-makers who evaluate outcomes, usability, and evidence before adoption.
Purchase or access systems for outpatient BPH treatment in selected settings.
Support sales, training, and market development outside the United States.
Access the systems through sales-type leasing rather than outright purchase.
Strategy
The company’s strategy is to expand the installed base of robotic systems, increase procedure utilization, and grow recurring handpiece sales tied to each surgery. It also invests in next-generation product development, software, and AI-enabled planning tools to improve Aquablation therapy and strengthen its competitive position.
More installed systems create future recurring handpiece and service revenue.
Higher production volumes can reduce per-unit costs and support margins.
Product improvements help sustain differentiation versus surgical and non-surgical alternatives.
Coverage and payment determine whether hospitals and physicians adopt the therapy.
Geography
Q2/2026The United States is the company’s core market and accounted for 88% of revenue in 2025, with 12% from outside the United States. Manufacturing is centered in San Jose, California, while logistics and shipping rely on third-party providers in the United States, United Kingdom, and the Netherlands to serve global customers.
Share of the revenue the company reports by geography.
Risks
The business depends on clinical adoption, reimbursement coverage, and continued regulatory compliance for a medical device platform used in surgery. It also faces manufacturing, supplier, and product-safety risks because the systems rely on regulated components, single-source suppliers, and post-market surveillance.
- Reimbursement and coverage riskImpact: HighLikelihood: Medium
Hospitals and physicians may not adopt Aquablation if payers do not cover the procedure adequately.
Exposure: U.S. and international markets
- Product safety and recall riskImpact: HighLikelihood: Medium
Adverse events, malfunctions, or manufacturing defects can trigger recalls, reporting obligations, or market restrictions.
Exposure: Robotic systems and handpieces
- Supplier concentration riskImpact: HighLikelihood: Medium
Many components are sourced from single-source suppliers, so disruptions can affect production and delivery.
Exposure: Manufacturing supply chain
- Regulatory compliance riskImpact: HighLikelihood: Medium
Failure to meet FDA and other device regulations can lead to delays, sanctions, or loss of approvals.
Exposure: U.S. and international regulatory regimes
- Competitive pressureImpact: MediumLikelihood: Medium
The company competes against established surgical and non-surgical BPH treatments with broader brand recognition and reimbursement coverage.
Exposure: BPH treatment market
Accounting
Judgemental itemsDifferent contract types can recognize revenue at different times and affect quarterly comparability.
Impact: Systems, handpieces, leases, and service contracts
Lease arrangements change the timing and classification of revenue and receivables.
Impact: Capital equipment sales channel
Estimated warranty, repair, and surveillance costs affect cost of sales and liabilities.
Impact: Robotic systems and handpieces
U.S. versus international mix can change average selling prices and gross margin from period to period.
Impact: Revenue and gross margin
Single-source components and manufacturing scaling can require reserves or write-downs if demand or supply shifts.
Impact: Cost of sales and inventory valuation
Similar listed companies
Publicly listed companies with a comparable business focus.
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Provectus Biopharmaceuticals, Inc.
PVCT · Pharmaceutical Preparations
Bioventus Inc.
BVS · Surgical & Medical Instruments & Apparatus
Advanced Biomed Inc.
ADVB · Services-Medical Laboratories
UFP Technologies, Inc
UFPT · Surgical & Medical Instruments & Apparatus
UFP Technologies is a U.S.-based contract development and manufacturing company focused on single-use and single-patient medical devices and components.
Globus Medical, Inc
GMED · Surgical & Medical Instruments & Apparatus
Globus Medical is a U.S.-based medical device company focused on musculoskeletal care, with products used in spine, orthopedic trauma, hip, knee, extremity and neurosurgical procedures.
Last updated: 24/09/2026